Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Repligen Narrows FY2025 Adj EPS Guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 Est; Raises FY2025 Sales Guidance from $715.000M-$735.000M to $729.000M-$737.000M vs $726.458M Est

Author: Benzinga Newsdesk | October 28, 2025 06:31am
Repligen (NASDAQ:RGEN) narrows FY2025 Adj EPS guidance from $1.65-$1.72 to $1.65-$1.68 vs $1.68 analyst estimate. Raises FY2025 sales outlook from $715.000 million-$735.000 million to $729.000 million-$737.000 million vs $726.458 million estimate.

Posted In: RGEN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist